Moderna’s move on August 19 was not a short squeeze or a meme-driven spike. It was a platform re-rating. When Merck and Moderna announced that intismeran autogene, their personalized mRNA cancer vaccine (V940/mRNA-4157), met both primary endpoints in the Phase 3 INTerpath-001 trial for melanoma, the stock went from $62.96 to close at $174.38, a gain of about 177%, on volume of roughly 199 million shares versus about 4.3 million the prior session. That kind of volume does not come from retail momentum. Institutions re-underwrote an entirely new valuation framework in a single session.
The science behind the move matters for sizing the trade. Intismeran is built from a sample of each patient’s own tumor and designed to teach the immune system to recognize that individual cancer’s specific mutations. Combined with Merck’s Keytruda, the regimen met its primary endpoints of recurrence-free survival and distant metastasis-free survival in patients with completely resected Stage IIB-IV melanoma. This is a positive Phase 3 topline readout for an mRNA-based individualized neoantigen therapy, and analysts immediately framed it as platform validation, not a single-drug win.
That framing is where the trade lives. Merck and Moderna are already running trials across non-small cell lung cancer, bladder cancer, and renal cell carcinoma. William Blair noted that the Phase 2 renal cell carcinoma program could be positioned as a pivotal-style study, with timing dependent on event accrual and sponsor updates. Barclays raised its price target to $125 from $48. Wolfe Research upgraded from Underperform to Peer Perform.
Since the initial spike, MRNA has chopped inside a wide range as funds buy dips and others fade strength. The stock closed at $158.83 on August 25 after trading as high as about $161 that day, with the 50-period moving average far below current price and momentum indicators still elevated but off peak readings. The consolidation range is the entry zone. A break above $175 with volume would signal a fresh leg; a slip below $140 suggests the re-rating is complete and the market is waiting for hard FDA submission timing.
The risks are real. Moderna is still burning cash, and management has guided to about $2.9 billion of R&D expense for 2026. The company has not yet released the full quantitative data from the melanoma Phase 3 trial. A norovirus Phase 3 interim analysis earlier this year did not meet statistical criteria for early success, a reminder that pipeline setbacks arrive without warning. The FDA submission for intismeran has not been announced as filed. Until it is, the oncology optionality the market is assigning remains based on topline results and expectations about the path to approval.
The next binary event is the renal cell carcinoma Phase 2 readout, with timing dependent on trial progress and company guidance. Position size matters here. MRNA at $155 is a fundamentally different risk from MRNA at $63, and the short-term valuation tension is real. But the platform case, validated for the first time at Phase 3, is not going away.